Array-based comparative genomic hybridization analysis reveals chromosomal copy number aberrations associated with clinical outcome in canine diffuse large B-cell lymphoma

• Published in: PloS one 2014-11, Vol.9 (11), p.e111817-e111817
• Main Authors: Aricò, Arianna, Ferraresso, Serena, Bresolin, Silvia, Marconato, Laura, Comazzi, Stefano, Te Kronnie, Geertruy, Aresu, Luca
• Format: Article
• Language: English
• Subjects: Aberration; Animals; Artificial chromosomes; B-cell lymphoma; Bioindicators; Biology and Life Sciences; Biomarkers; Cancer; Cancer therapies; Chemotherapy; Chromosome Aberrations; Comparative analysis; Comparative Genomic Hybridization; Copy number; Cytogenetics; Dehydrogenases; Deoxyribonucleic acid; DNA; DNA Copy Number Variations; Dogs; Food science; Gene expression; Genetic aspects; Genetic testing; Genetics; Genomes; Heavy chains; HSF1 protein; Humans; Hybridization; Hybridization analysis; Immunoglobulins; Lymphatic system; Lymphocytes B; Lymphoma; Lymphoma, Large B-Cell, Diffuse - genetics; Lymphoma, Large B-Cell, Diffuse - metabolism; Medical prognosis; Metabolic Networks and Pathways; Mutation; Myc protein; Non-Hodgkin's lymphomas; Patient outcomes; Prognosis; Remission; Therapy; Tumorigenesis; Tumors; Vaccines
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0111817

Canine Diffuse Large B-cell Lymphoma (cDLBCL) is an aggressive cancer with variable clinical response. Despite recent attempts by gene expression profiling to identify the dog as a potential animal model for human DLBCL, this tumor remains biologically heterogeneous with no prognostic biomarkers to predict prognosis. The aim of this work was to identify copy number aberrations (CNAs) by high-resolution array comparative genomic hybridization (aCGH) in 12 dogs with newly diagnosed DLBCL. In a subset of these dogs, the genetic profiles at the end of therapy and at relapse were also assessed. In primary DLBCLs, 90 different genomic imbalances were counted, consisting of 46 gains and 44 losses. Two gains in chr13 were significantly correlated with clinical stage. In addition, specific regions of gains and losses were significantly associated to duration of remission. In primary DLBCLs, individual variability was found, however 14 recurrent CNAs (>30%) were identified. Losses involving IGK, IGL and IGH were always found, and gains along the length of chr13 and chr31 were often observed (>41%). In these segments, MYC, LDHB, HSF1, KIT and PDGFRα are annotated. At the end of therapy, dogs in remission showed four new CNAs, whereas three new CNAs were observed in dogs at relapse compared with the previous profiles. One ex novo CNA, involving TCR, was present in dogs in remission after therapy, possibly induced by the autologous vaccine. Overall, aCGH identified small CNAs associated with outcome, which, along with future expression studies, may reveal target genes relevant to cDLBCL.